Global Testicular Cancer Drugs Market 2014-2018

Global Testicular Cancer Drugs Market 2014-2018

Category : Pharmaceuticals
Published On : January  2014
Pages : 52

------------ Or -------------

TechNavio's analysts forecast the Global Testicular Cancer Drugs market to grow at a CAGR of 4.02 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of testicular cancer. The Global Testicular Cancer Drugs market has also been witnessing the emergence of combination therapies for the treatment of testicular cancer. However, the presence of alternative testicular cancer treatments could pose a challenge to the growth of this market. 
TechNavio's report, the Global Testicular Cancer Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market market in the Americas, and the EMEA and APAC regions; it also covers the Global Testicular Cancer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Bristol-Myers Squibb Co., Hospira Inc., Teva Pharmaceutical Industries Ltd., and ZIOPHARM Oncology Inc.
Other vendors mentioned in the report are Baxter International Inc., Fresenius Kabi Pharmaceuticals Holding Inc., and Mylan Pharmaceutical Inc. 
Key questions answered in this report: 
What will the market size be in 2016/2018 and what will be the growth rate?
What are key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report.


01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Testicular Cancer by Type

07.1.1 Seminoma

07.1.2 Non-seminoma

08. Testicular Cancer Disease by Stages

08.1.1 Stage 0

08.1.2 Stage I

08.1.3 Stage II

08.1.4 Stage III

09. Treatment Options

09.1 Surgery

09.2 Radiation Therapy

09.3 Chemotherapy

10. Clinical Trial Snapshot

11. Geographical Segmentation

11.1 Global Testicular Cancer Drugs Market by Geographical Segmentation

12. Buying Criteria

13. Rate of Incidence and Prevalence

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

20.1 Competitive Scenario

20.1.1 Key News

20.1.2 Acquisitions

20.2 Other Prominent Vendors

21. Key Vendor Analysis

21.1 Bristol-Myers Squibb Co.

21.1.1 Business Overview

21.1.2 Key Information

21.1.3 SWOT Analysis

21.2 Hospira Inc.

21.2.1 Business Overview

21.2.2 Business Segmentation

21.2.3 Key Information

21.2.4 SWOT Analysis

21.3 Teva Pharmaceutical Industries Ltd.

21.3.1 Business Overview

21.3.2 Business Segmentation

21.3.3 Key Information

21.3.4 SWOT Analysis

21.4 ZIOPHARM Oncology Inc.

21.4.1 Business Overview

21.4.2 Key Information

21.4.3 SWOT Analysis

22. Other Reports in this Series

List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Global Testicular Cancer Drugs market 2013-2018 (US$ million)

Exhibit 3: Testicular Cancer Segmentation by Type

Exhibit 4: Global Testicular Cancer Drugs Market by Geographical Segmentation 2013 (percent)

Exhibit 5: Business Segmentation of Hospira Inc.

Exhibit 6: Business Segmentation of Teva Pharmaceutical Industries Ltd.

Enquiry Before Buy